

3 July 2014

## Aqua Bio Technology and Restorsea dispute resolved

**Aqua Bio Technology ASA (Oslo Axess: ABT) and Restorsea Inc. today announced that their previously announced dispute has been resolved. The parties have agreed to continue and strengthen their relationship.**

Restorsea filed a complaint by a New York court in February, claiming violation of its exclusivity rights for ABT's skin care ingredient Aquabeautine XL™. Restorsea has agreed to withdraw the complaint and the legal proceedings have been irrevocably settled. An amended supply, license, and exclusivity agreement has been signed to strengthen the partnership between Restorsea and ABT. All financial elements are unchanged and both parties will cover their own expenses related to the complaint filed.

The new agreement between the parties grants Restorsea exclusivity rights not just for Aquabeautine XL™, but also for the ABT ingredients Dermaclarine™ and Beauty Propelline™, as well as rights for non-medical uses to any future ingredients that may be developed from fish hatching fluids and certain future ingredients that may be developed from the hatching fluids of other animals. Further sales of these ingredients by ABT to other customers have been terminated.

In a joint comment on the new agreement, ABT's Chairman John Afseth and Restorsea's Chairman Muneer Satter, said: "We are extremely pleased that we have been able to settle our disagreement in such a positive way. Both companies look forward to further expanding the commercial success of Restorsea and ABT's hatching fluid technology together in a more extensive partnership."

*For further information, please call John Afseth, Chairman, telephone +47 9220 1850 or Arvid Lindberg, CEO, telephone +47 9824 5410*

*Aqua Bio Technology ASA (ABT) develops, produces and markets patented ingredients and technologies to the international cosmetic and skin care industry. ABT's ingredients Aquabeautine XL™, Dermaclarine™ and Beauty Propelline™ are marine solutions with distinctly individual and unique properties, derived from the hatching fluid of salmon. ABT is listed on the Oslo Stock Exchange's Axess market.*